The price of Inozyme Pharma Inc (NASDAQ: INZY) closed at $7.39 in the last session, up 9.00% from day before closing price of $6.78. In other words, the price has increased by $+0.61 from its previous closing price. On the day, 1251636 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at INZY’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 13.36 and its Current Ratio is at 13.36. In the meantime, Its Debt-to-Equity ratio is 0.33 whereas as Long-Term Debt/Eq ratio is at 0.33.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Jefferies on March 23, 2023, Upgraded its rating to Buy and sets its target price to $6 from $4.50 previously.
On May 26, 2022, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On February 07, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $33.H.C. Wainwright initiated its Buy rating on February 07, 2022, with a $33 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 01 ’23 when Hopfner Robert Lorne bought 833,333 shares for $4.80 per share. The transaction valued at 3,999,998 led to the insider holds 2,923,110 shares of the business.
Pivotal bioVenture Partners Fu bought 833,333 shares of INZY for $3,999,998 on Aug 01 ’23. The Director now owns 2,923,110 shares after completing the transaction at $4.80 per share. On May 12 ’23, another insider, Hopfner Robert Lorne, who serves as the Director of the company, bought 228,702 shares for $6.25 each. As a result, the insider paid 1,429,388 and bolstered with 3,661,518 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, INZY now has a Market Capitalization of 457.11M and an Enterprise Value of 315.12M.
Stock Price History:
Over the past 52 weeks, INZY has reached a high of $7.33, while it has fallen to a 52-week low of $2.69. The 50-Day Moving Average of the stock is 5.67, while the 200-Day Moving Average is calculated to be 4.76.
Shares Statistics:
According to the various share statistics, INZY traded on average about 516.95K shares per day over the past 3-months and 827.13k shares per day over the past 10 days. A total of 61.77M shares are outstanding, with a floating share count of 41.16M. Insiders hold about 33.38% of the company’s shares, while institutions hold 60.15% stake in the company. Shares short for INZY as of Feb 29, 2024 were 2.32M with a Short Ratio of 4.61, compared to 2.87M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 3.76% and a Short% of Float of 3.78%.
Earnings Estimates
The company has 6 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.36 for the current quarter, with a high estimate of -$0.3 and a low estimate of -$0.39, while EPS last year was -$0.4. The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.27 and low estimates of -$0.41.
Analysts are recommending an EPS of between -$1.1 and -$1.67 for the fiscal current year, implying an average EPS of -$1.5. EPS for the following year is -$1.6, with 6 analysts recommending between -$1.3 and -$1.89.
